Compare CRDL & HCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDL | HCKT |
|---|---|---|
| Founded | 2017 | 1991 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.6M | 249.5M |
| IPO Year | 2017 | 1998 |
| Metric | CRDL | HCKT |
|---|---|---|
| Price | $0.97 | $13.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $8.55 | ★ $17.33 |
| AVG Volume (30 Days) | ★ 764.3K | 207.4K |
| Earning Date | 11-20-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 3.61% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.49 |
| Revenue | N/A | ★ $285,862,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.57 |
| P/E Ratio | ★ N/A | $27.10 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.88 | $9.16 |
| 52 Week High | $2.34 | $20.68 |
| Indicator | CRDL | HCKT |
|---|---|---|
| Relative Strength Index (RSI) | 28.32 | 73.34 |
| Support Level | $0.94 | $12.39 |
| Resistance Level | $1.10 | $14.30 |
| Average True Range (ATR) | 0.06 | 0.55 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 20.33 | 64.88 |
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.